A new study reports a promising cell therapy for osteosarcoma, a bone cancer that is especially difficult to treat once it spreads. While survival rates for localized disease are about 70%, they fall below 30% when the cancer metastasizes, most often to the lungs. Treatment options have remained largely unchanged for decades, relying on surgery and chemotherapy, highlighting the need for new approaches.
Researchers developed a next-generation therapy using engineered natural killer (NK) cells that target a protein called CD70, which is commonly found on aggressive osteosarcoma cells but rarely on normal tissues. These “armored” cells were enhanced with additional features to improve their performance, including a built-in growth signal to help them survive longer and a protective mechanism to resist the tumor’s ability to shut down immune responses.
In laboratory tests, the engineered cells showed near-complete destruction of cancer cells and released strong immune-activating signals. In mouse models, the therapy slowed tumor growth, improved survival, and notably prevented the spread of cancer to the lungs. The findings suggest this multi-enhanced CAR-NK therapy could move into clinical trials as a potential new treatment for patients with advanced or treatment-resistant osteosarcoma.